ClinicalTrials.gg
CompletedNCT06388187Updated May 5, 2026

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

A Phase 3 interventional study of Cagrilintide and Semaglutide in Obesity, sponsored by Novo Nordisk A/S. Completed at 25 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.

Enrollment
13th of 36
300 · median 154
Started
2024
with 5 others
Phase 3
15 of 36
4 open now
Registered
19th of 36
by date
Lead sponsor
36 of 36
Novo Nordisk A/S

Among the 36 studies testing cagrilintide in Obesity, this one is the 13th largest by enrollment, is one of 6 that started in 2024, is one of 15 in phase 3, and was the 19th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cagrilintide in Obesity, or all of them as a file.
02

Study summary

This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Age above or equal to 18 years at the time of signing

    1. (BMI) greater than or equal to (≥) 30.0 kilogram per meter square (kg/m\^2) or
    2. BMI ≥27.0 kg/m2 with the presence of at least one obesity related complication including, but not limited to hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease

Exclusion criteria

Exclusion Criteria:

  • (HbA1c) ≥6.5% (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening
  • History of type 1 or type 2 diabetes
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    CagriSema Dose 1

    Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 60 weeks.

    Drug: Cagrilintide · Drug: Semaglutide

  • Placebo comparator
    Placebo Dose 1

    Participants will receive once-weekly s.c injection of placebo matched to cagrisema dose 1 (cagrilintide and semaglutide) for 68 weeks.

    Drug: Placebo

  • Active comparator
    CagriSema Dose 2

    Participants will receive once-weekly s.c injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 12-week dose escalation period until target dose (dose 2) of CagriSema(cagrilintide and semaglutide) is achieved and maintained up to 56 weeks.

    Drug: Cagrilintide · Drug: Semaglutide

  • Placebo comparator
    Placebo Dose 2

    Participants will receive once-weekly s.c injection of placebo matched to cagrisema dose 2 (cagrilintide and semaglutide) for 68 weeks.

    Drug: Placebo

Interventions

  • Participants will receive once-weekly cagrilintide subcutaneously.

  • Participants will receive once-weekly semaglutide subcutaneously.

  • DrugPlacebo

    Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously.

06

What researchers measure

Primary outcomes

  1. Relative change in body weight

    Measured in percentage (%).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  2. Achievement of ≥5% weight reduction

    Measured as count of participant.

    Time frame: From baseline (week 0) to end of treatment (week 68)

Secondary outcomes

  1. Achievement of ≥10% weight reduction

    Measured as count of participant.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  2. Achievement of ≥15% weight reduction

    Measured as count of participant.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  3. Achievement of ≥20% weight reduction

    Measured as count of participant.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  4. Change in waist circumference

    Measured in centimeter (cm).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  5. Change in systolic blood pressure

    Measured in millimeters of mercury.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  6. Ratio to baseline in lipids: Total cholesterol

    Measured in ratio.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  7. Ratio to baseline in lipids: High-density lipoprotein (HDL) cholesterol

    Measured in ratio.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  8. Ratio to baseline in lipids: Low-density lipoprotein (LDL) cholesterol

    Measured in ratio.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  9. Ratio to baseline in lipids: Very low-density lipoprotein (VLDL) cholesterol

    Measured in ratio.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  10. Ratio to baseline in lipids: Triglycerides

    Measured in ratio.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  11. Ratio to baseline in lipids: Free fatty acids

    Measured in ratio.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  12. Number of treatment emergent adverse events (TEAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to end of study (week 74)

  13. Number of treatment emergent serious adverse events (TESAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to end of study (week 74)

07

Study locations

25 sites
  • Aurora FDRC Inc.
    Costa Mesa, California 92627, United States
  • Clinical Trial Res Assoc,Inc
    Plantation, Florida 33324, United States
  • Midwest Inst For Clin Res
    Indianapolis, Indiana 46260, United States
  • Accellacare
    Wilmington, North Carolina 28401, United States
  • Velocity Clinical Res-Dallas
    Dallas, Texas 75230, United States
  • Washington Cntr Weight Mgmt
    Arlington, Virginia 22206, United States
  • Capital Clin Res Ctr,LLC
    Olympia, Washington 98502, United States
  • Ocean West Research Clinic
    Surrey, British Columbia V3Z 2N6, Canada
  • Nova Scotia Health Authority
    Halifax, Nova Scotia B3H 1V7, Canada
  • Wharton Medical Clinic Clinical Trials (Hamilton)
    Hamilton, Ontario L8L 5G8, Canada
  • Hospices Civils de Lyon-Hopital Lyon Sud-1
    Pierre-Bénite, 69310, France
  • Hospices Civils de Lyon-Hopital Lyon Sud
    Pierre-Bénite, 69310, France
  • Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec
    Saint-Herblain, 44800, France
  • Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil
    Toulouse, 31059, France
  • InnoDiab Forschung GmbH
    Essen, 45136, Germany
  • Wendisch - Dahl Hamburg - DZHW
    Hamburg, 22607, Germany
  • AmBeNet GmbH
    Leipzig, 04107, Germany
  • Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
    Münster, 48145, Germany
  • Forschungszentrum Ruhr KliFoCenter GmbH, Kahrmann
    Witten, 58455, Germany
  • The Health Centre
    Bradford-on-Avon, BA15 1DQ, United Kingdom
  • Southmead Hospital
    Bristol, BS10 5NB, United Kingdom
  • Addenbrooke's Hospital_Cambridge
    Cambridge, CB2 0QQ, United Kingdom
  • University Hospital Coventry - WISDEM Centre
    Coventry, CV2 2DX, United Kingdom
  • Staploe Medical Centre
    Soham, CB7 5JD, United Kingdom
  • Joint Clinical Research Facility - Swansea
    Swansea, SA2 8PP, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Apr 2026, 21 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 21 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2024
First posted
Apr 29, 2024
StartActual
Jun 24, 2024
Primary completionActual
Apr 22, 2026
CompletionActual
Apr 22, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06388187
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 29, 2024
Start date
Jun 24, 2024
Primary completion
Apr 22, 2026
Completion
Apr 22, 2026
Last update
May 5, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion